Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1999 Jan;45:114–124.

Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.

R E Heisey 1, J C Carroll 1, E Warner 1, D R McCready 1, V Goel 1
PMCID: PMC2328074  PMID: 10889864

Abstract

OBJECTIVES: To present a strategy for identifying candidates for consideration of BRCA1 and BRCA2 mutation testing. To discuss the implications of identifying patients as BRCA1 or BRCA2 mutation carriers, and to provide recommendations for managing them. QUALITY OF EVIDENCE: A MEDLINE search from January 1990 to May 1998 was performed using the terms genetic breast screening, BRCA1, and BRCA2. The bibliographies of articles found were searched for further relevant titles. There are no published, randomized controlled clinical trials of management strategies for known BRCA carriers. Many recommendations for management are based on expert opinion only. MAIN FINDINGS: About 5% of women with breast cancer are carriers of genetic mutations. An accurate and detailed family history is the most important tool for identifying potential BRCA1 and BRCA2 mutation carriers. Women identified as carriers have a substantially increased risk of breast and ovarian cancer. Male carriers have a moderately increased risk of prostate cancer. Management strategies for carriers are not well studied but include increased surveillance, preventive surgery, chemoprevention, and lifestyle modification. CONCLUSION: Family physicians must be able to identify people at risk, to discuss management strategies, and when appropriate, to offer referral for consideration of genetic testing. There is an urgent need for research to determine the effectiveness of surveillance strategies, preventive surgery, chemoprevention, and lifestyle modification for BRCA1 and BRCA2 mutation carriers.

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biesecker B. B., Boehnke M., Calzone K., Markel D. S., Garber J. E., Collins F. S., Weber B. L. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993 Apr 21;269(15):1970–1974. [PubMed] [Google Scholar]
  2. Blackwood M. A., Weber B. L. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998 May;16(5):1969–1977. doi: 10.1200/JCO.1998.16.5.1969. [DOI] [PubMed] [Google Scholar]
  3. Blankson M. L., Cliver S. P., Goldenberg R. L., Hickey C. A., Jin J., Dubard M. B. Health behavior and outcomes in sequential pregnancies of black and white adolescents. JAMA. 1993 Mar 17;269(11):1401–1403. [PubMed] [Google Scholar]
  4. Bourne T. H., Campbell S., Reynolds K. M., Whitehead M. I., Hampson J., Royston P., Crayford T. J., Collins W. P. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993 Apr 17;306(6884):1025–1029. doi: 10.1136/bmj.306.6884.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burke W., Daly M., Garber J., Botkin J., Kahn M. J., Lynch P., McTiernan A., Offit K., Perlman J., Petersen G. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997 Mar 26;277(12):997–1003. [PubMed] [Google Scholar]
  6. Cannistra S. A. Cancer of the ovary. N Engl J Med. 1993 Nov 18;329(21):1550–1559. doi: 10.1056/NEJM199311183292108. [DOI] [PubMed] [Google Scholar]
  7. Cole D. E., Gallinger S., McCready D. R., Rosen B., Engel J., Malkin D. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? CMAJ. 1996 Jan 15;154(2):149–155. [PMC free article] [PubMed] [Google Scholar]
  8. Couch F. J., DeShano M. L., Blackwood M. A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. doi: 10.1056/NEJM199705153362002. [DOI] [PubMed] [Google Scholar]
  9. Easton D. F., Bishop D. T., Ford D., Crockford G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993 Apr;52(4):678–701. [PMC free article] [PubMed] [Google Scholar]
  10. Easton D. Breast cancer genes--what are the real risks? Nat Genet. 1997 Jul;16(3):210–211. doi: 10.1038/ng0797-210. [DOI] [PubMed] [Google Scholar]
  11. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  12. Ford D., Easton D. F. The genetics of breast and ovarian cancer. Br J Cancer. 1995 Oct;72(4):805–812. doi: 10.1038/bjc.1995.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Foulkes W. D., Narod S. A. Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Clin Invest Med. 1995 Dec;18(6):473–483. [PubMed] [Google Scholar]
  14. Goel V. Tamoxifen and breast cancer prevention: what should you tell your patients? CMAJ. 1998 Jun 16;158(12):1615–1617. [PMC free article] [PubMed] [Google Scholar]
  15. Goodnight J. E., Jr, Quagliana J. M., Morton D. L. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 1984 Jul;26(3):198–201. doi: 10.1002/jso.2930260313. [DOI] [PubMed] [Google Scholar]
  16. Gross T. P., Schlesselman J. J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 1994 Mar;83(3):419–424. [PubMed] [Google Scholar]
  17. Harvey B. J., Miller A. B., Baines C. J., Corey P. N. Effect of breast self-examination techniques on the risk of death from breast cancer. CMAJ. 1997 Nov 1;157(9):1205–1212. [PMC free article] [PubMed] [Google Scholar]
  18. Hoskins K. F., Stopfer J. E., Calzone K. A., Merajver S. D., Rebbeck T. R., Garber J. E., Weber B. L. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995 Feb 15;273(7):577–585. [PubMed] [Google Scholar]
  19. Jacobs I., Davies A. P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J. G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17;306(6884):1030–1034. doi: 10.1136/bmj.306.6884.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Littrup P. J. Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1994 Oct 1;74(7 Suppl):2016–2022. doi: 10.1002/1097-0142(19941001)74:7+<2016::aid-cncr2820741705>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  21. Lynch H. T., Lynch J., Conway T., Watson P., Feunteun J., Lenoir G., Narod S., Fitzgibbons R., Jr Hereditary breast cancer and family cancer syndromes. World J Surg. 1994 Jan-Feb;18(1):21–31. doi: 10.1007/BF00348188. [DOI] [PubMed] [Google Scholar]
  22. Margolese R. G. How do we interpret the results of the Breast Cancer Prevention trial? CMAJ. 1998 Jun 16;158(12):1613–1614. [PMC free article] [PubMed] [Google Scholar]
  23. Marx G. Possible function found for breast cancer genes. Science. 1997 Apr 25;276(5312):531–532. doi: 10.1126/science.276.5312.531. [DOI] [PubMed] [Google Scholar]
  24. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  25. Nelson N. J. Studies show prophylactic surgeries seem to reduce cancer risk. J Natl Cancer Inst. 1997 Jun 4;89(11):762–763. doi: 10.1093/jnci/89.11.762. [DOI] [PubMed] [Google Scholar]
  26. Offit K. BRCA1. A new marker in the management of patients with breast cancer? Cancer. 1996 Feb 15;77(4):599–601. doi: 10.1002/(SICI)1097-0142(19960215)77:4<599::AID-CNCR2>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  27. Pennisi V. R., Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg. 1989 Winter;13(1):15–21. doi: 10.1007/BF01570320. [DOI] [PubMed] [Google Scholar]
  28. Piver M. S., Baker T. R., Jishi M. F., Sandecki A. M., Tsukada Y., Natarajan N., Mettlin C. J., Blake C. A. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer. 1993 Jan 15;71(2 Suppl):582–588. doi: 10.1002/cncr.2820710214. [DOI] [PubMed] [Google Scholar]
  29. Piver M. S., Jishi M. F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993 May 1;71(9):2751–2755. doi: 10.1002/1097-0142(19930501)71:9<2751::aid-cncr2820710911>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  30. Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. doi: 10.1093/jnci/87.9.645. [DOI] [PubMed] [Google Scholar]
  31. Schrag D., Kuntz K. M., Garber J. E., Weeks J. C. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997 May 15;336(20):1465–1471. doi: 10.1056/NEJM199705153362022. [DOI] [PubMed] [Google Scholar]
  32. Stephenson J. Study shows mastectomy prevents breast cancer in high-risk women. JAMA. 1997 May 14;277(18):1421–1422. [PubMed] [Google Scholar]
  33. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  34. Thomas D. B., Gao D. L., Self S. G., Allison C. J., Tao Y., Mahloch J., Ray R., Qin Q., Presley R., Porter P. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. 1997 Mar 5;89(5):355–365. doi: 10.1093/jnci/89.5.355. [DOI] [PubMed] [Google Scholar]
  35. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. doi: 10.1038/ng0596-117. [DOI] [PubMed] [Google Scholar]
  36. Thune I., Brenn T., Lund E., Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997 May 1;336(18):1269–1275. doi: 10.1056/NEJM199705013361801. [DOI] [PubMed] [Google Scholar]
  37. Tobacman J. K., Greene M. H., Tucker M. A., Costa J., Kase R., Fraumeni J. F., Jr Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982 Oct 9;2(8302):795–797. doi: 10.1016/s0140-6736(82)92681-2. [DOI] [PubMed] [Google Scholar]
  38. Vasen H. F. Screening in breast cancer families: is it useful? Ann Med. 1994 Jun;26(3):185–190. doi: 10.3109/07853899409147888. [DOI] [PubMed] [Google Scholar]
  39. Weber B. L., Giusti R. M., Liu E. T. Developing strategies for intervention and prevention in hereditary breast cancer. J Natl Cancer Inst Monogr. 1995;(17):99–102. [PubMed] [Google Scholar]
  40. Woolf S. H. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 1995 Nov 23;333(21):1401–1405. doi: 10.1056/NEJM199511233332107. [DOI] [PubMed] [Google Scholar]
  41. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]
  42. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. doi: 10.1126/science.8091231. [DOI] [PubMed] [Google Scholar]
  43. Ziegler L. D., Kroll S. S. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 1991 Oct;14(5):451–454. doi: 10.1097/00000421-199110000-00018. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES